Skip to main content
. Author manuscript; available in PMC: 2016 Jul 14.
Published in final edited form as: Sci Transl Med. 2016 Jan 27;8(323):323ra12. doi: 10.1126/scitranslmed.aad2195

Fig. 1. Effects of mipomersen treatment on human lipoprotein lipids and apoB levels.

Fig. 1

Blood samples were obtained from subjects during their kinetic studies performed after 3 weeks of treatment with placebo and after 7 weeks of treatment with mipomersen. Plasma was separated from those samples, and VLDL, IDL, and LDL were isolated by sequential ultracentrifugation. (A and B) Cholesterol and TG were measured by enzymatic methods. (C) ApoB was determined by commercial enzyme-linked immunosorbent assay. Data are means ± SD (n = 5 samples obtained from each of the 17 subjects during their two kinetic studies). P values determined by paired t tests after determining that the data were normally distributed using the Kolmogorov-Smirnov normality test.